Trade Vertex Pharmaceuticals Incorporated - VRTX CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.51
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$4.32)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.13)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$4.32)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.13)

Key Stats

• Prev. Close: 556.67
• Open: 551.45
• 1-Year Change: 39.17%
• Day's Range: 544.71 - 554.67

Trade Vertex Pharmaceuticals Incorporated - VRTX

Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that develops and commercialises innovative medicines. 

Founded in 1989, Vertex is headquartered in Boston, Massachusetts, with international headquarters in London, UK. The company focuses on health conditions like cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, duchenne muscular dystrophy and type 1 diabetes.

The company designed and developed Symdeko/Symkevi, Orkambi and Kalydeco for cystic fibrosis, and Trikafta for patients aged six years or older with at least one F508del mutation. There are several products in the pipeline, such as VX-864 for the treatment of AAT deficiency, VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, VX- 880 for Type 1 Diabetes and VX-548, a NaV1.8 inhibitor for treatments of neuropathic and musculoskeletal pain.

Vertex sells its products to specialty pharmacies and distributors, hospitals and clinics. It has collaborations and partnership deals with CRISPR Therapeutics AG, Moderna, Arbor Biotechnologies and several other pharma companies that support the commercialisation of drugs.

The company went public in 1991. Vertex Pharmaceuticals Incorporated stock trades on the Nasdaq under the ticker symbol VRTX. 

You can follow the VRTX share value and price movement live through stock charts at Capital.com.